Is cobenfy safe? I’m sorta worried about it. I see my psych in a few days.
But I think I want to try it.
I am on 3 antipsychotics rn and I don’t want TD from Haldol.
I think cobenfy might be the answer for me if it’s safe. I hope it works wonders.
Is cobenfy safe? I’m sorta worried about it. I see my psych in a few days.
But I think I want to try it.
I am on 3 antipsychotics rn and I don’t want TD from Haldol.
I think cobenfy might be the answer for me if it’s safe. I hope it works wonders.
Is it even out yet?
It’s supposed to be available starting sometime in October, I hope karXT is worth the hype.
My understanding is it will be extremely expensive. I even heard $1200/month
Does anyone know if this is an add on AP or a stand alone drug?
I may give it a shot
@everhopeful
I just looked it up. It’s listed at $1850 per month! That’s impossible to afford
cobenfy is approved as monotherapy.
It’s not approved to be used with another AP.
Ok thanks @everhopeful
My Mom and pdoc want me to try it but Im doing fine on invega just want to lower the dose
@Ribbit If you do try it please let us know what your experience is on it.
Will do! @Vinegar
I read they are doing trials for it as an add on to a second antipsychotic treatment too. I think the trial is called ARISE.
It’s not FDA approved for add on yet but they are studying it from what I understand @everhopeful @Wave
Here is what I read (it says I’m new and can’t put the link. It can be found on Clinical Trials Arena website):
“Cobenfy is also being developed as an adjunctive therapy in patients who have an inadequate response to atypical antipsychotic monotherapy. The ongoing Phase III ARISE trial is a six-week, randomised, double-blind, placebo-controlled, multicentre, outpatient study in patients with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. At present, although physicians will occasionally prescribe a second antipsychotic or antidepressant off-label to augment the effects of an antipsychotic, there are no approved combination therapeutic regimens for schizophrenia. Furthermore, KOLs reported only modest improvements in efficacy and increased side-effect burden with this type of polypharmacy. If positive results are found in the ongoing ARISE trial, Cobenfy could be the first approved adjunctive therapy for the treatment of schizophrenia.”
This topic was automatically closed 90 days after the last reply. New replies are no longer allowed.